Cancer and Age: General Considerations

Hoffe, Sarah E.; Balducci, L.

doi:10.1016/j.cger.2011.09.001

Cited by 65 publications

(41 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Red/processed meat consumption was significantly associated with mortality in participants >45 years, while it was not significant for younger participants. As expected, younger participants had few deaths, being age the main risk factor for CV disease [46] and cancer [47]. The interaction with age is also plausible because of the time lag needed for the pathophysiologic development of these conditions.…”

Section: Discussionsupporting

confidence: 64%

Should we recommend reductions in saturated fat intake or in red/processed meat consumption? The SUN prospective cohort study

Bes–Rastrollo

Basterra-Gortari

et al. 2018

Clinical Nutrition

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 64%

Should we recommend reductions in saturated fat intake or in red/processed meat consumption? The SUN prospective cohort study

Bes–Rastrollo

Basterra-Gortari

et al. 2018

Clinical Nutrition

View full text Add to dashboard Cite

“…Approximately 50% of new lung cancer cases are diagnosed in patients aged more than 70 years, and about 15% in patients aged more than 80 years [19]. Aging may be associated with decreased physiologic reserve, comorbidity and polypharmacy, functional dependence, and inadequate social support, which lead to limited life expectancy with a potential reduced tolerance to cancer chemotherapy [20]. Furthermore, elderly patients are underrepresented in clinical trials and many treatment decisions are based on results of trials conducted in substantially younger individuals [21].…”

Section: Concerns In the Use Of Cisplatin And Carboplatinmentioning

confidence: 98%

Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles

Rossi

Maïo

2016

Expert Review of Anticancer Therapy

179

124

View full text Add to dashboard Cite

Platinum-based chemotherapy remains the standard-of-care for most patients affected by advanced non-small cell lung cancer (NSCLC). The platinum compounds currently used in NSCLC are cisplatin and carboplatin. The availability of new generation drugs has led to the adoption of schedules with lower doses of platinum compounds leading to increased tolerability. Several data suggest that third generation cisplatin-based regimens are slightly superior to carboplatin-based chemotherapy, with a different safety profile, and so cisplatin should remain the standard reference for the treatment of selected patients with advanced NSCLC. Recent evidence emphasized that the optimal number of first-line platinum cycles should be four for any NSCLC histology. New platinum compounds and the use of functional genomics to deliver platinum drugs as personalised medicine, are being investigated. Here we review the current status of cisplatin and carboplatin regimens looking to the future role of platinum compounds in advanced NSCLC patients.

show abstract

“…That observation is likely a result of the nature of lung cancer patients, who are more likely to have a lower socioeconomic status, to come from an ethnic minority group, and to be elderly 2 . Older patients often have comorbid conditions, reduced functioning, and less physical reserve to tolerate treatment 26,27 . Those sociodemographic factors might in part explain the nature of the unmet needs seen in lung cancer patients.…”

Section: Discussionmentioning

confidence: 99%

The Prevalence and Nature of Supportive Care Needs in Lung Cancer Patients

et al. 2016

View full text Add to dashboard Cite

PurposeIn the present work, we set out to comprehensively describe the unmet supportive care and information needs of lung cancer patients. MethodsThis cross-sectional study used the Supportive Care Needs Survey Short Form 34 (34 items) and an informational needs survey (8 items). Patients with primary lung cancer in any phase of survivorship were included. Demographic data and treatment details were collected from the medical charts of participants. The unmet needs were determined overall and by domain. Univariable and multivariable regression analyses were performed to determine factors associated with greater unmet needs. were recruited. The mean number of unmet needs was 8 (range: 0-34), and 69 patients (78%) reported at least 1 unmet need. The need proportions by domain were 52% health system and information, 66% psychological, 58% physical, 24% patient care, and 20% sexuality. The top 2 unmet needs were "fears of the cancer spreading" [n = 44 of 84 (52%)] and "lack of energy/tiredness" [n = 42 of 88 (48%)]. On multivariable analysis, more advanced disease and higher MD Anderson Symptom Inventory scores were associated with increased unmet needs. Patients reported that the most desired information needs were those for information on managing symptoms such as fatigue (78%), shortness of breath (77%), and cough (63%). ResultsConclusions Unmet supportive care needs are common in lung cancer patients, with some patients experiencing a very high number of unmet needs. Further work is needed to develop resources to address those needs.

show abstract

Cancer and Age: General Considerations

Cited by 65 publications

References 75 publications

Should we recommend reductions in saturated fat intake or in red/processed meat consumption? The SUN prospective cohort study

Should we recommend reductions in saturated fat intake or in red/processed meat consumption? The SUN prospective cohort study

Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles

The Prevalence and Nature of Supportive Care Needs in Lung Cancer Patients

Contact Info

Product

Resources

About